{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,21]],"date-time":"2026-04-21T16:28:03Z","timestamp":1776788883308,"version":"3.51.2"},"reference-count":20,"publisher":"Springer Science and Business Media LLC","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":[],"published-print":{"date-parts":[[2024,4,13]]},"DOI":"10.7759\/cureus.58164","type":"journal-article","created":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T07:51:35Z","timestamp":1712994695000},"source":"Crossref","is-referenced-by-count":5,"title":["High-Dose Colchicine: Key Factor in the Treatment of Morbidly Obese COVID-19 Patients"],"prefix":"10.7759","author":[{"given":"Tsanko","family":"Mondeshki","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Vanyo","family":"Mitev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","reference":[{"key":"ref1","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2020.11127","article-title":"Obesity\u00a0\u2011\u00a0a risk factor for increased COVID\u201119 prevalence, severity and lethality (review)","volume":"22","author":"Petrakis D","year":"2020","unstructured":"Petrakis D, Margin\u0103 D, Tsarouhas K, et al.. Obesity\u00a0\u2011\u00a0a risk factor for increased COVID\u201119 prevalence, severity and lethality (review). Mol Med Rep. 2020, 22:9-19. 10.3892\/mmr.2020.11127","journal-title":"Mol Med Rep"},{"key":"ref2","doi-asserted-by":"publisher","DOI":"10.3389\/fendo.2022.780872","article-title":"Association of obesity with COVID-19 severity and mortality: an updated systemic review, meta-analysis, and meta-regression","volume":"13","author":"Singh R","year":"2022","unstructured":"Singh R, Rathore SS, Khan H, et al.. Association of obesity with COVID-19 severity and mortality: an updated systemic review, meta-analysis, and meta-regression. Front Endocrinol (Lausanne). 2022, 13:780872. 10.3389\/fendo.2022.780872","journal-title":"Front Endocrinol (Lausanne)"},{"key":"ref3","doi-asserted-by":"publisher","DOI":"10.1002\/oby.22859","article-title":"Association of obesity with disease severity among patients with coronavirus disease 2019","volume":"28","author":"Kalligeros M","year":"2020","unstructured":"Kalligeros M, Shehadeh F, Mylona EK, Benitez G, Beckwith CG, Chan PA, Mylonakis E. Association of obesity with disease severity among patients with coronavirus disease 2019. Obesity (Silver Spring). 2020, 28:1200-4. 10.1002\/oby.22859","journal-title":"Obesity (Silver Spring)"},{"key":"ref4","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCULATIONAHA.120.051936","article-title":"Association of body mass index and age with morbidity and mortality in patients hospitalized with COVID-19: results from the American Heart Association COVID-19 Cardiovascular Disease Registry","volume":"143","author":"Hendren NS","year":"2021","unstructured":"Hendren NS, de Lemos JA, Ayers C, et al.. Association of body mass index and age with morbidity and mortality in patients hospitalized with COVID-19: results from the American Heart Association COVID-19 Cardiovascular Disease Registry. Circulation. 2021, 143:135-44. 10.1161\/CIRCULATIONAHA.120.051936","journal-title":"Circulation"},{"key":"ref5","doi-asserted-by":"publisher","DOI":"10.1038\/s41392-020-00454-7","article-title":"Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches","volume":"5","author":"Jin Y","year":"2020","unstructured":"Jin Y, Ji W, Yang H, Chen S, Zhang W, Duan G. Endothelial activation and dysfunction in COVID-19: from basic mechanisms to potential therapeutic approaches. Signal Transduct Target Ther. 2020, 5:293. 10.1038\/s41392-020-00454-7","journal-title":"Signal Transduct Target Ther"},{"key":"ref6","doi-asserted-by":"publisher","DOI":"10.3892\/mmr.2022.12867","article-title":"Role of endothelial dysfunction in the severity of COVID\u201119 infection (review)","volume":"26","author":"Kadiyska T","year":"2022","unstructured":"Kadiyska T, Tourtourikov I, Dabchev K, et al.. Role of endothelial dysfunction in the severity of COVID\u201119 infection (review). Mol Med Rep. 2022, 26:351. 10.3892\/mmr.2022.12867","journal-title":"Mol Med Rep"},{"key":"ref7","unstructured":"WHO. Obesity and overweight. (2024). https.\/\/www.who.int\/news-room\/fact-sheets\/detail\/obesity-and-overweight."},{"key":"ref8","doi-asserted-by":"publisher","DOI":"10.5114\/aoms.2016.58928","article-title":"Obesity and inflammation: the linking mechanism and the complications","volume":"13","author":"Ellulu MS","year":"2017","unstructured":"Ellulu MS, Patimah I, Khaza'ai H, Rahmat A, Abed Y. Obesity and inflammation: the linking mechanism and the complications. Arch Med Sci. 2017, 13:851-63. 10.5114\/aoms.2016.58928","journal-title":"Arch Med Sci"},{"key":"ref9","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.30269","article-title":"Complete, rapid resolution of severe bilateral pneumonia and acute respiratory distress syndrome in a COVID-19 patient: role for a unique therapeutic combination of inhalations with bromhexine, higher doses of colchicine, and hymecromone","volume":"14","author":"Mondeshki T","year":"2022","unstructured":"Mondeshki T, Bilyukov R, Tomov T, Mihaylov M, Mitev V. Complete, rapid resolution of severe bilateral pneumonia and acute respiratory distress syndrome in a COVID-19 patient: role for a unique therapeutic combination of inhalations with bromhexine, higher doses of colchicine, and hymecromone. Cureus. 2022, 14:e30269. 10.7759\/cureus.30269","journal-title":"Cureus"},{"key":"ref10","doi-asserted-by":"publisher","DOI":"10.22541\/au.171008530.09561084\/v1","article-title":"Effect of increasing doses of colchicine on the treatment of 333 COVID-19 inpatients. [PREPRINT]","author":"Tiholov R","year":"2024","unstructured":"Tiholov R, Lilov A, Georgieva G, Palaveev K, Tashkov K, Mitev V. Effect of increasing doses of colchicine on the treatment of 333 COVID-19 inpatients. [PREPRINT].  Authorea. 2024, 10.22541\/au.171008530.09561084\/v1","journal-title":"Authorea"},{"key":"ref11","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.35909","article-title":"Effect of an accidental colchicine overdose in a COVID-19 inpatient with bilateral pneumonia and pericardial effusion","volume":"15","author":"Mondeshki T","year":"2023","unstructured":"Mondeshki T, Bilyukov R, Mitev V. Effect of an accidental colchicine overdose in a COVID-19 inpatient with bilateral pneumonia and pericardial effusion. Cureus. 2023, 15:e35909. 10.7759\/cureus.35909","journal-title":"Cureus"},{"key":"ref12","doi-asserted-by":"publisher","DOI":"10.3897\/pharmacia.70.e112550","article-title":"Comparison of treatment of COVID-19 with inhaled bromhexine, higher doses of colchicine and hymecromone with WHO-recommended Paxlovid, molnupiravir, remdesivir, anti-IL-6 receptor antibodies and baricitinib","volume":"70","author":"Mitev V","year":"2023","unstructured":"Mitev V. Comparison of treatment of COVID-19 with inhaled bromhexine, higher doses of colchicine and hymecromone with WHO-recommended Paxlovid, molnupiravir, remdesivir, anti-IL-6 receptor antibodies and baricitinib. Pharmacia. 2023, 70:1177-93. 10.3897\/pharmacia.70.e112550","journal-title":"Pharmacia"},{"key":"ref13","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.54441","article-title":"High doses of colchicine act as \u201csilver bullets\u201d against severe COVID-19","volume":"16","author":"Lilov A","year":"2024","unstructured":"Lilov A, Palaveev K, Mitev V. High doses of colchicine act as \u201csilver bullets\u201d against severe COVID-19. Cureus. 2024, 16:e54441. 10.7759\/cureus.54441","journal-title":"Cureus"},{"key":"ref14","doi-asserted-by":"publisher","DOI":"10.3389\/fimmu.2020.01518","article-title":"Targeting the NLRP3 inflammasome in severe COVID-19","volume":"11","author":"Freeman TL","year":"2020","unstructured":"Freeman TL, Swartz TH. Targeting the NLRP3 inflammasome in severe COVID-19. Front Immunol. 2020, 11:1518. 10.3389\/fimmu.2020.01518","journal-title":"Front Immunol"},{"key":"ref15","doi-asserted-by":"publisher","DOI":"10.7759\/cureus.34221","article-title":"Remdesivir-associated acute liver failure in a COVID-19 patient: a case report and literature review","volume":"15","author":"Ahmed-Khan MA","year":"2023","unstructured":"Ahmed-Khan MA, Matar G, Coombes K, Moin K, Joseph BM, Funk CM. Remdesivir-associated acute liver failure in a COVID-19 patient: a case report and literature review. Cureus. 2023, 15:e34221. 10.7759\/cureus.34221","journal-title":"Cureus"},{"key":"ref16","doi-asserted-by":"publisher","DOI":"10.1093\/infdis\/jiab247","article-title":"\u03b2-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells","volume":"224","author":"Zhou S","year":"2021","unstructured":"Zhou S, Hill CS, Sarkar S, et al.. \u03b2-d-N4-hydroxycytidine inhibits SARS-CoV-2 through lethal mutagenesis but is also mutagenic to mammalian cells. J Infect Dis. 2021, 224:415-9. 10.1093\/infdis\/jiab247","journal-title":"J Infect Dis"},{"key":"ref17","doi-asserted-by":"publisher","DOI":"10.1136\/bmj.n2663","article-title":"Buyer beware: molnupiravir may damage DNA","volume":"375","author":"van Schalkwyk JM","year":"2021","unstructured":"van Schalkwyk JM. Buyer beware: molnupiravir may damage DNA. BMJ. 2021, 375:n2663. 10.1136\/bmj.n2663","journal-title":"BMJ"},{"key":"ref18","doi-asserted-by":"publisher","DOI":"10.3390\/v15071451","article-title":"Targeting inflammasome activation in viral infection: a therapeutic solution?","volume":"15","author":"Deng CH","year":"2023","unstructured":"Deng CH, Li TQ, Zhang W, Zhao Q, Wang Y. Targeting inflammasome activation in viral infection: a therapeutic solution?. Viruses. 2023, 15:1451. 10.3390\/v15071451","journal-title":"Viruses"},{"key":"ref19","unstructured":"How many people die from the flu?. (2022). https.\/\/ourworldindata.org\/influenza-deaths."},{"key":"ref20","doi-asserted-by":"publisher","DOI":"10.1080\/13102818.2023.2288240","article-title":"What is the lowest lethal dose of colchicine?","volume":"37","author":"Mitev V","year":"2023","unstructured":"Mitev V. What is the lowest lethal dose of colchicine?. Biotechnol Biotechnol Equip. 2023, 37:2288240. 10.1080\/13102818.2023.2288240","journal-title":"Biotechnol Biotechnol Equip"}],"container-title":["Cureus"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.cureus.com\/articles\/239046-high-dose-colchicine-key-factor-in-the-treatment-of-morbidly-obese-covid-19-patients","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,4,13]],"date-time":"2024-04-13T07:51:40Z","timestamp":1712994700000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.cureus.com\/articles\/239046-high-dose-colchicine-key-factor-in-the-treatment-of-morbidly-obese-covid-19-patients"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2024,4,13]]},"references-count":20,"URL":"https:\/\/doi.org\/10.7759\/cureus.58164","relation":{},"ISSN":["2168-8184"],"issn-type":[{"value":"2168-8184","type":"print"}],"subject":[],"published":{"date-parts":[[2024,4,13]]}}}